/ /

Laird Harrison
Smartphones hold implications for retinal screening, beyond
The advent of smartphone devices and applications is transforming the practice of ophthalmology, especially in regard to ophthalmic diagnosis and monitoring.
Steroids may be preferable to anti-VEGF for DME in certain cases
Two-year study results highlight some advantages of steroid treatment for DME.
Photoactivation holds promise for keratitis treatment
Photoactivation holds promise for keratitis treatment
The same photoactivation process used in collagen cross-linking for keratoconus can kill bacteria without the need for the oxygen responsible for the biomechanical effects, potentially pointing toward better treatments for keratitis, according to Olivier Richoz, MD, PhD.
Topography disparity effectively detects subclinical keratoconus
Topography disparity can even provide a useful parameter for diagnosing the subclinical form of the disease, said David P. Piñero, PhD, and colleagues from the Medimar International Hospital, Alicante, Spain.
Virtual trial designed to explore AMD monitoring
Constructing vignettes from retina images and data can serve as a useful low-cost alternative to clinical trials for evaluating different screening approaches, researchers said. The researchers, from seven British medical centres, have taken this approach in a virtual trial to determine whether community optometrists can assess the risk that quiescent neovascular age-related macular degeneration (AMD) lesions can reawaken.
Eyes with hypotony may fail less often after trabeculectomy
Eyes with hypotony after trabeculectomy might fare better than those without hypotony, a new study shows.
Managing functional visual field loss with low IOP
When visual field defects progress despite good IOP control, clinicians should look for other factors, according to Malik Y. Kahook, MD.
Glaucoma cure may be found in newly discovered biomarkers
The study of biomarkers for glaucoma is pointing to promising avenues for new treatments, according to Vivek J. Srinivasan, PhD.
A bullish view: Navigating beyond glaucoma company mistakes
Companies specializing in glaucoma products can make billions of dollars, but only if they can find a path through a minefield of scientific, regulatory, and marketing hazards, according to Richard A. Lewis, MD.
How success in glaucoma innovation must come from within
Companies that want to sell glaucoma products must start by building their own scientific expertise, said David E.I. Pyott, CBE, who was Allergan’s chief executive officer (CEO) and chairman of its board of directors from 1998 to 2015.


View Results